中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2011年
6期
731-733
,共3页
癌,移行细胞%投药,膀胱内,热疗
癌,移行細胞%投藥,膀胱內,熱療
암,이행세포%투약,방광내,열료
Carcinoma,transitional cell%Administration,intravesical%Hyperthmia
目的 探讨膀胱癌术后进行热灌注化疗对胰岛素样生长因子(IGF)、肿瘤坏死因子(TNF)的影响.方法 回顾性分析64例膀胱移行细胞癌患者,术后进行膀胱热灌注化疗(热化疗组)和灌注化疗(化疗组)各32例;治疗前、治疗后2周、治疗后4周监测IGF、TNF的变化.结果 治疗前、治疗后2周、治疗后4周热化疗组IGF分别为(65.97±5.25)μg/L、(49.93 ±1.98)μg/L、(36.82±1.89)μg/L;化疗组IGF分别为(61.87±5.41)μg/L、(57.86±2.18)μg/L、(48.68±2.26)μg/L.热化疗组TNF分别为(2.32±0.36)μg/L、(3.84±0.31)μg/L、(8.79±0.46)μg/L;化疗组TNF分别为(2.21±0.19)μg/L、(2.89±0.47)μg/L、(3.87±0.61)μg/L.热化疗2周对细胞因子浓度的影响比化疗组明显,并随治疗时间的延长其影响愈加明显,差异均有统计学意义(均P＜0.05).结论 热灌注化疗可更好地调节机体的免疫状态,对抑制膀胱癌的生长和复发具有重要意义.
目的 探討膀胱癌術後進行熱灌註化療對胰島素樣生長因子(IGF)、腫瘤壞死因子(TNF)的影響.方法 迴顧性分析64例膀胱移行細胞癌患者,術後進行膀胱熱灌註化療(熱化療組)和灌註化療(化療組)各32例;治療前、治療後2週、治療後4週鑑測IGF、TNF的變化.結果 治療前、治療後2週、治療後4週熱化療組IGF分彆為(65.97±5.25)μg/L、(49.93 ±1.98)μg/L、(36.82±1.89)μg/L;化療組IGF分彆為(61.87±5.41)μg/L、(57.86±2.18)μg/L、(48.68±2.26)μg/L.熱化療組TNF分彆為(2.32±0.36)μg/L、(3.84±0.31)μg/L、(8.79±0.46)μg/L;化療組TNF分彆為(2.21±0.19)μg/L、(2.89±0.47)μg/L、(3.87±0.61)μg/L.熱化療2週對細胞因子濃度的影響比化療組明顯,併隨治療時間的延長其影響愈加明顯,差異均有統計學意義(均P＜0.05).結論 熱灌註化療可更好地調節機體的免疫狀態,對抑製膀胱癌的生長和複髮具有重要意義.
목적 탐토방광암술후진행열관주화료대이도소양생장인자(IGF)、종류배사인자(TNF)적영향.방법 회고성분석64례방광이행세포암환자,술후진행방광열관주화료(열화료조)화관주화료(화료조)각32례;치료전、치료후2주、치료후4주감측IGF、TNF적변화.결과 치료전、치료후2주、치료후4주열화료조IGF분별위(65.97±5.25)μg/L、(49.93 ±1.98)μg/L、(36.82±1.89)μg/L;화료조IGF분별위(61.87±5.41)μg/L、(57.86±2.18)μg/L、(48.68±2.26)μg/L.열화료조TNF분별위(2.32±0.36)μg/L、(3.84±0.31)μg/L、(8.79±0.46)μg/L;화료조TNF분별위(2.21±0.19)μg/L、(2.89±0.47)μg/L、(3.87±0.61)μg/L.열화료2주대세포인자농도적영향비화료조명현,병수치료시간적연장기영향유가명현,차이균유통계학의의(균P＜0.05).결론 열관주화료가경호지조절궤체적면역상태,대억제방광암적생장화복발구유중요의의.
Objective To explore the influence of intravesical chemotherapy combined with hyperthmia on levels of insulin growth factor( IGF) and tumor necrosis factor( TNF) in bladder cancer after operation. Methods 64 cases of transitional cell carcinoma of bladder accepted TURBt were randomly divided into two groups: intravesical chemotherapy combined with hyperthmia group and intravesical chemotherapy group. Levels of ICF and TNF in two weeks before therapy 、two weeks after therapy, four weeks after therapy were tested. Results The IGF levels were (65.97±5.25)μg/L,(49.93±1.98)μg/L,(36.82±1.89)μg/L in intravesical chemotherapy combined with hyperthmia group and(61.87 ±5.41)μg/L, (57.86 ±2. 18) μg/L, (48. 68 ±2. 26) μg/L in intravesical chemotherapy group. The TNF levels were(2.32 ±0. 36)μg/L, (3. 84 ±0. 31) μg/L, (8. 79 ±0. 46)μg/L in intravesical chemotherapy combined with hyperthmia group and(2. 21 ±0. 19)μg/L,(2. 89 ±0.47) μg/L, (3. 87 ±0.61)μg/L in intravesical chemotherapy group. The influence of intravesical chemotherapy with hyperthmia on levels of IGF and TNF were significant than intravesical chemotherap, and the influence degree showed in time-dependent manner (all P ＜ 0. 05 ). Conclusion Intravesical chemotherapy combined with hyperthmia had curative effect in inhibiting the recurrence of tumor after operation.
